Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region
Data(s) |
2016
22/01/2019
|
---|---|
Resumo |
Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region. Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3. © 2016 The Authors. |
Formato |
application/pdf |
Identificador |
ISSN 2405-8521 |
Idioma(s) |
eng |
Direitos |
info:eu-repo/semantics/openAccess |
Fonte |
Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women (2015) N. Engl. J. Med., 372, pp. 711-723 |
Palavras-Chave | #Human papillomavirus #Cervical cancer #Cervical intraepithelial neoplasia #Adenocarcinoma in situ #616.544 #Papiloma #Neoplasmas #Adenocarcinoma in Situ #Wart Virus Vaccine #Adenocarcinoma In Situ #Age Distribution #Article #Condyloma Acuminatum #Genotype #Geographic Distribution #Health Program #Human #Human Papillomavirus Type 11 #Human Papillomavirus Type 16 #Human Papillomavirus Type 18 #Human Papillomavirus Type 31 #Human Papillomavirus Type 33 #Human Papillomavirus Type 45 #Human Papillomavirus Type 52 #Human Papillomavirus Type 58 #Human Papillomavirus Type 6 #Immunization #Infection Risk #Mixed Infection #Molecular Epidemiology #Nonhuman #Prevalence #Priority Journal #Systematic Review #Uterine Cervix Carcinoma In Situ #Virus Detection #Wart Virus #Adenocarcinoma #Adolescent #Adult #Asia #Classification #Europe #Female #Genetics #Isolation And Purification #Middle Aged #North America #Papillomaviridae #Randomized Controlled Trial (Topic) #South And Central America #Uterine Cervix Carcinoma In Situ #Virology #Young Adult #Adenocarcinoma #Adolescent #Adult #Asia #Cervical Intraepithelial Neoplasia #Europe #Female #Genotype #Humans #Latin America #Middle Aged #North America #Papillomaviridae #Randomized Controlled Trials As Topic #Young Adult |
Tipo |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |